{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:25:57Z","timestamp":1793701557084,"version":"4.5.1"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS- 2024-00334820"],"award-info":[{"award-number":["RS- 2024-00334820"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS- 2024-00431505"],"award-info":[{"award-number":["RS- 2024-00431505"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002630","name":"Ewha Womans University","doi-asserted-by":"publisher","award":["2023-0416-001"],"award-info":[{"award-number":["2023-0416-001"]}],"id":[{"id":"10.13039\/501100002630","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118754","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T21:40:16Z","timestamp":1763070016000},"page":"118754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Targeting PRMT5 in cancer: Mechanistic insights and clinical progress"],"prefix":"10.1016","volume":"193","author":[{"given":"Joohyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiye","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4479-9374","authenticated-orcid":false,"given":"Inah","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.biopha.2025.118754_bib1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00159-8","article-title":"Protein arginine methylation: from enigmatic functions to therapeutic targeting","volume":"20","author":"Wu","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"15","key":"10.1016\/j.biopha.2025.118754_bib2","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1007\/s00018-019-03140-2","article-title":"Cellular consequences of arginine methylation","volume":"76","author":"Lorton","year":"2019","journal-title":"Cell Mol. Life Sci."},{"issue":"5","key":"10.1016\/j.biopha.2025.118754_bib3","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s12276-021-00613-y","article-title":"Protein arginine methyltransferases: promising targets for cancer therapy","volume":"53","author":"Hwang","year":"2021","journal-title":"Exp. Mol. Med"},{"key":"10.1016\/j.biopha.2025.118754_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107859","article-title":"Medicinal chemistry insights into PRMT5 inhibitors","volume":"153","author":"Jiao","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2025.118754_bib5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1039\/C4MD00269E","article-title":"Structural biology and chemistry of protein arginine methyltransferases","volume":"5","author":"Schapira","year":"2014","journal-title":"Medchemcomm"},{"issue":"9","key":"10.1016\/j.biopha.2025.118754_bib6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41580-019-0166-7","article-title":"Author correction: the regulation, functions and clinical relevance of arginine methylation","volume":"20","author":"Guccione","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2025.118754_bib7","article-title":"A comprehensive investigation of PRMT5 in the prognosis and ion channel features of lung cancer","volume":"14","author":"Wang","year":"2024","journal-title":"Front Oncol."},{"issue":"20","key":"10.1016\/j.biopha.2025.118754_bib8","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1128\/MCB.00923-08","article-title":"Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells","volume":"28","author":"Wang","year":"2008","journal-title":"Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118754_bib9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/neuonc\/nox206","article-title":"PRMT5 as a druggable target for glioblastoma therapy","volume":"20","author":"Banasavadi-Siddegowda","year":"2018","journal-title":"Neuro Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118754_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074710","article-title":"PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1","volume":"8","author":"Nicholas","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2025.118754_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1042\/BJ20120768","article-title":"Protein arginine methyltransferase 5 is essential for growth of lung cancer cells","volume":"446","author":"Gu","year":"2012","journal-title":"Biochem J."},{"issue":"5","key":"10.1016\/j.biopha.2025.118754_bib12","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/cam4.2114","article-title":"Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers","volume":"8","author":"Vinet","year":"2019","journal-title":"Cancer Med"},{"issue":"41","key":"10.1016\/j.biopha.2025.118754_bib13","doi-asserted-by":"crossref","first-page":"67532","DOI":"10.18632\/oncotarget.11376","article-title":"Protein arginine methylation\/demethylation and cancer","volume":"7","author":"Poulard","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.biopha.2025.118754_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.15698\/cst2020.08.228","article-title":"PRMT5 function and targeting in cancer","volume":"4","author":"Kim","year":"2020","journal-title":"Cell Stress"},{"issue":"10","key":"10.1016\/j.biopha.2025.118754_bib15","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.celrep.2018.08.002","article-title":"PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes","volume":"24","author":"Hamard","year":"2018","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/s41467-021-21204-5","article-title":"PRMT5 inhibition disrupts splicing and stemness in glioblastoma","volume":"12","author":"Sachamitr","year":"2021","journal-title":"Nat. Commun."},{"issue":"44","key":"10.1016\/j.biopha.2025.118754_bib17","doi-asserted-by":"crossref","first-page":"17960","DOI":"10.1073\/pnas.1209814109","article-title":"Crystal structure of the human PRMT5:MEP50 complex","volume":"109","author":"Antonysamy","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.biopha.2025.118754_bib18","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00018-015-1847-9","article-title":"The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond","volume":"72","author":"Stopa","year":"2015","journal-title":"Cell Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118754_bib19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.36401\/JIPO-22-1","article-title":"Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review","volume":"5","author":"Feustel","year":"2022","journal-title":"J. Immunother. Precis Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118754_bib20","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2025.118754_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102264","article-title":"TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers","volume":"52","author":"Briggs","year":"2025","journal-title":"Transl. Oncol."},{"issue":"17","key":"10.1016\/j.biopha.2025.118754_bib22","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1016\/j.molcel.2021.07.019","article-title":"Molecular basis for substrate recruitment to the PRMT5 methylosome","volume":"81","author":"Mulvaney","year":"2021","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.biopha.2025.118754_bib23","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/ncb1413","article-title":"Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse germ cells","volume":"8","author":"Ancelin","year":"2006","journal-title":"Nat. Cell Biol."},{"issue":"32","key":"10.1016\/j.biopha.2025.118754_bib24","doi-asserted-by":"crossref","first-page":"21347","DOI":"10.1074\/jbc.M109.015578","article-title":"Role of pICLn in methylation of Sm proteins by PRMT5","volume":"284","author":"Pesiridis","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2025.118754_bib25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/embor.2008.45","article-title":"The histone-binding protein COPR5 is required for nuclear functions of the protein arginine methyltransferase PRMT5","volume":"9","author":"Lacroix","year":"2008","journal-title":"EMBO Rep."},{"issue":"3","key":"10.1016\/j.biopha.2025.118754_bib26","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1074\/jbc.M110.148486","article-title":"RioK1, a new interactor of protein arginine methyltransferase 5 (PRMT5), competes with pICln for binding and modulates PRMT5 complex composition and substrate specificity","volume":"286","author":"Guderian","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2025.118754_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057008","article-title":"Structure of the arginine methyltransferase PRMT5-MEP50 reveals a mechanism for substrate specificity","volume":"8","author":"Ho","year":"2013","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.biopha.2025.118754_bib28","doi-asserted-by":"crossref","first-page":"9630","DOI":"10.1128\/MCB.24.21.9630-9645.2004","article-title":"Human SWI\/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes","volume":"24","author":"Pal","year":"2004","journal-title":"Mol. Cell Biol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118754_bib29","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1038\/s41418-021-00786-z","article-title":"Snail\/PRMT5\/NuRD complex contributes to DNA hypermethylation in cervical cancer by TET1 inhibition","volume":"28","author":"Gao","year":"2021","journal-title":"Cell Death Differ."},{"issue":"3","key":"10.1016\/j.biopha.2025.118754_bib30","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nsmb.1568","article-title":"PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing","volume":"16","author":"Zhao","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118754_bib31","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.7150\/thno.42047","article-title":"PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression","volume":"10","author":"Liu","year":"2020","journal-title":"Theranostics"},{"issue":"13","key":"10.1016\/j.biopha.2025.118754_bib32","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1093\/nar\/gky461","article-title":"PHD finger protein 1 (PHF1) is a novel reader for histone H4R3 symmetric dimethylation and coordinates with PRMT5-WDR77\/CRL4B complex to promote tumorigenesis","volume":"46","author":"Liu","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"10.1016\/j.biopha.2025.118754_bib33","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.7150\/thno.53023","article-title":"PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression","volume":"11","author":"Yang","year":"2021","journal-title":"Theranostics"},{"issue":"26","key":"10.1016\/j.biopha.2025.118754_bib34","doi-asserted-by":"crossref","first-page":"22799","DOI":"10.18632\/oncotarget.4332","article-title":"Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.biopha.2025.118754_bib35","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/onc.2016.287","article-title":"Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth","volume":"36","author":"Deng","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118754_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2025.111925","article-title":"PRMT5-FOXM1 axis activates beta-catenin\/IL8 signaling to drive angiogenesis of gastric cancer","volume":"134","author":"Liu","year":"2025","journal-title":"Cell Signal"},{"issue":"12","key":"10.1016\/j.biopha.2025.118754_bib37","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1016\/j.celrep.2017.11.096","article-title":"PRMT5 is a critical regulator of breast cancer stem cell function via histone methylation and FOXP1 expression","volume":"21","author":"Chiang","year":"2017","journal-title":"Cell Rep."},{"issue":"33","key":"10.1016\/j.biopha.2025.118754_bib38","doi-asserted-by":"crossref","first-page":"54809","DOI":"10.18632\/oncotarget.18957","article-title":"A novel SHARPIN-PRMT5-H3R2me1 axis is essential for lung cancer cell invasion","volume":"8","author":"Fu","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib39","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1038\/s41467-019-11696-7","article-title":"Genotoxic stress-triggered beta-catenin\/JDP2\/PRMT5 complex facilitates reestablishing glutathione homeostasis","volume":"10","author":"Cao","year":"2019","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2025.118754_bib40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/leu.2015.308","article-title":"The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation","volume":"30","author":"Tarighat","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.biopha.2025.118754_bib41","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1172\/JCI85239","article-title":"Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia","volume":"126","author":"Jin","year":"2016","journal-title":"J. Clin. Invest"},{"issue":"5","key":"10.1016\/j.biopha.2025.118754_bib42","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0021-9258(17)49877-2","article-title":"Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma","volume":"295","author":"Karkhanis","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118754_bib43","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.fob.2015.02.003","article-title":"Kruppel-like factor 4 induces apoptosis and inhibits tumorigenic progression in SK-BR-3 breast cancer cells","volume":"5","author":"Wang","year":"2015","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.biopha.2025.118754_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.gene.2017.02.025","article-title":"Kruppel-like factor 4 (KLF4): What we currently know","volume":"611","author":"Ghaleb","year":"2017","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib45","doi-asserted-by":"crossref","first-page":"8419","DOI":"10.1038\/ncomms9419","article-title":"Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis","volume":"6","author":"Hu","year":"2015","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.biopha.2025.118754_bib46","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1111\/cas.14910","article-title":"The roles and regulation of the KLF5 transcription factor in cancers","volume":"112","author":"Luo","year":"2021","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.biopha.2025.118754_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.17856","article-title":"PRMT5 activates KLF5 by methylation to facilitate lung cancer","volume":"28","author":"Zhou","year":"2024","journal-title":"J. Cell Mol. Med"},{"issue":"10","key":"10.1016\/j.biopha.2025.118754_bib48","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202302009","article-title":"PRMT5 triggers glucocorticoid-induced cell migration in triple-negative breast cancer","volume":"6","author":"Noureddine","year":"2023","journal-title":"Life Sci. Alliance"},{"issue":"5","key":"10.1016\/j.biopha.2025.118754_bib49","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/0008-5472.CAN-15-1766","article-title":"Arginine Methylation of SREBP1a via PRMT5 Promotes De Novo Lipogenesis and Tumor Growth","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res"},{"issue":"33","key":"10.1016\/j.biopha.2025.118754_bib50","doi-asserted-by":"crossref","first-page":"13516","DOI":"10.1073\/pnas.1311784110","article-title":"PRMT5 dimethylates R30 of the p65 subunit to activate NF-\u03baB","volume":"110","author":"Wei","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"19","key":"10.1016\/j.biopha.2025.118754_bib51","doi-asserted-by":"crossref","first-page":"7019","DOI":"10.1128\/MCB.23.19.7019-7029.2003","article-title":"Purification and identification of a novel complex which is involved in androgen receptor-dependent transcription","volume":"23","author":"Hosohata","year":"2003","journal-title":"Mol. Cell Biol."},{"issue":"18","key":"10.1016\/j.biopha.2025.118754_bib52","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175023","article-title":"PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression","volume":"134","author":"Yan","year":"2024","journal-title":"J. Clin. Invest"},{"issue":"19","key":"10.1016\/j.biopha.2025.118754_bib53","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2018-02-831438","article-title":"PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival","volume":"132","author":"Lu","year":"2018","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.biopha.2025.118754_bib54","doi-asserted-by":"crossref","first-page":"12695","DOI":"10.1074\/jbc.M110.103911","article-title":"Methylation of ribosomal protein S10 by protein-arginine methyltransferase 5 regulates ribosome biogenesis","volume":"285","author":"Ren","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"13","key":"10.1016\/j.biopha.2025.118754_bib55","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41388-024-03264-1","article-title":"PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells","volume":"44","author":"Gillespie","year":"2025","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib56","doi-asserted-by":"crossref","first-page":"9711","DOI":"10.1038\/s41598-018-28002-y","article-title":"Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing","volume":"8","author":"Gerhart","year":"2018","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2025.118754_bib57","first-page":"4359","article-title":"PRMT5 regulates IRES-dependent translation via methylation of hnRNP A1","volume":"45","author":"Gao","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"10.1016\/j.biopha.2025.118754_bib58","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/ncb1802","article-title":"Arginine methylation regulates the p53 response","volume":"10","author":"Jansson","year":"2008","journal-title":"Nat. Cell Biol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118754_bib59","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.molcel.2017.01.019","article-title":"PRMT5-Dependent Methylation of the TIP60 Coactivator RUVBL1 Is a Key Regulator of Homologous Recombination","volume":"65","author":"Clarke","year":"2017","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib60","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s42003-020-01157-z","article-title":"PRMT5 promotes DNA repair through methylation of 53BP1 and is regulated by Src-mediated phosphorylation","volume":"3","author":"Hwang","year":"2020","journal-title":"Commun. Biol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118754_bib61","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/nchembio.422","article-title":"Methylation of FEN1 suppresses nearby phosphorylation and facilitates PCNA binding","volume":"6","author":"Guo","year":"2010","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118754_bib62","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2159-8290.CD-14-0625","article-title":"PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers","volume":"5","author":"Li","year":"2015","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.biopha.2025.118754_bib63","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184283","article-title":"High PRMT5 levels, maintained by KEAP1 inhibition, drive chemoresistance in high-grade serous ovarian cancer","volume":"135","author":"Ozturk","year":"2025","journal-title":"J. Clin. Invest"},{"issue":"4","key":"10.1016\/j.biopha.2025.118754_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115484","article-title":"PRMT5-mediated methylation of METTL3 promotes cisplatin resistance in ovarian cancer by facilitating DNA repair mechanisms","volume":"44","author":"Xia","year":"2025","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.biopha.2025.118754_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110940","article-title":"Interplay between symmetric arginine dimethylation and ubiquitylation regulates TDP1 proteostasis for the repair of topoisomerase I-DNA adducts","volume":"39","author":"Bhattacharjee","year":"2022","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.biopha.2025.118754_bib66","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1093\/nar\/gky291","article-title":"PRMT5-mediated arginine methylation of TDP1 for the repair of topoisomerase I covalent complexes","volume":"46","author":"Rehman","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib67","doi-asserted-by":"crossref","first-page":"191","DOI":"10.21037\/jgo-24-737","article-title":"PRMT5 attenuates regorafenib-induced DNA damage in hepatocellular carcinoma cells through symmetric dimethylation of RPL14","volume":"16","author":"Bi","year":"2025","journal-title":"J. Gastrointest. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib68","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.molcel.2013.08.039","article-title":"Arginine methylation-dependent reader-writer interplay governs growth control by E2F-1","volume":"52","author":"Zheng","year":"2013","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.biopha.2025.118754_bib69","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1158\/2159-8290.CD-20-0026","article-title":"PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2(V617F)-Mutant MPN","volume":"10","author":"Pastore","year":"2020","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.biopha.2025.118754_bib70","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41419-020-02771-9","article-title":"PRMT5 promotes cancer cell migration and invasion through the E2F pathway","volume":"11","author":"Barczak","year":"2020","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.biopha.2025.118754_bib71","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1158\/1541-7786.MCR-08-0197","article-title":"PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation","volume":"7","author":"Tanaka","year":"2009","journal-title":"Mol. Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib72","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41420-023-01299-z","article-title":"PRMT5-mediated regulatory arginine methylation of RIPK3","volume":"9","author":"Chauhan","year":"2023","journal-title":"Cell Death Discov."},{"issue":"2","key":"10.1016\/j.biopha.2025.118754_bib73","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.molcel.2008.09.013","article-title":"Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt","volume":"32","author":"Yamagata","year":"2008","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.biopha.2025.118754_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006890","article-title":"PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis","volume":"11","author":"Wang","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2025.118754_bib75","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41556-025-01610-3","article-title":"PRMT5-mediated arginine methylation stabilizes GPX4 to suppress ferroptosis in cancer","volume":"27","author":"Fan","year":"2025","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.biopha.2025.118754_bib76","article-title":"PRMT5-Mediated Arginine Methylation of ACSL4 Attenuates Its Stability and Suppresses Ferroptosis in Renal Cancer","volume":"8","author":"Zhang","year":"2025","journal-title":"Res. (Wash. D. C. )"},{"issue":"2","key":"10.1016\/j.biopha.2025.118754_bib77","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/ncb2158","article-title":"Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation","volume":"13","author":"Hsu","year":"2011","journal-title":"Nat. Cell Biol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118754_bib78","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.devcel.2018.06.025","article-title":"Loss of PRMT5 Promotes PDGFRalpha Degradation during Oligodendrocyte Differentiation and Myelination","volume":"46","author":"Calabretta","year":"2018","journal-title":"Dev. Cell"},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib79","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1038\/s41467-021-23833-2","article-title":"PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis","volume":"12","author":"Yin","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib80","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1038\/s41467-022-31645-1","article-title":"PRMT5 activates AKT via methylation to promote tumor metastasis","volume":"13","author":"Huang","year":"2022","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.biopha.2025.118754_bib81","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1158\/0008-5472.CAN-11-0458","article-title":"Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4","volume":"71","author":"Powers","year":"2011","journal-title":"Cancer Res."},{"issue":"13","key":"10.1016\/j.biopha.2025.118754_bib82","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.7150\/ijbs.115225","article-title":"PRMT1\/PRMT5-mediated differential arginine methylation of CRIP1 promotes the recurrence of small cell lung cancer after chemotherapy","volume":"21","author":"Han","year":"2025","journal-title":"Int J. Biol. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2025.118754_bib83","article-title":"PRMT5 Enables Robust STAT3 Activation via Arginine Symmetric Dimethylation of SMAD7","volume":"8","author":"Cai","year":"2021","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib84","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s42003-024-06290-7","article-title":"PRMT5-mediated methylation of STAT3 is required for lung cancer stem cell maintenance and tumour growth","volume":"7","author":"Abe","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.biopha.2025.118754_bib85","article-title":"PRMT5 Inhibition Promotes PD-L1 Expression and Immuno-Resistance in Lung Cancer","volume":"12","author":"Hu","year":"2021","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib86","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41420-024-02197-8","article-title":"CircGSK3beta mediates PD-L1 transcription through miR-338-3p\/PRMT5\/H3K4me3 to promote breast cancer cell immune evasion and tumor progression","volume":"10","author":"Liang","year":"2024","journal-title":"Cell Death Discov."},{"issue":"18","key":"10.1016\/j.biopha.2025.118754_bib87","doi-asserted-by":"crossref","first-page":"9162","DOI":"10.7150\/thno.59605","article-title":"PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression","volume":"11","author":"Jiang","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib88","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.apsb.2024.10.016","article-title":"Tumor-intrinsic PRMT5 upregulates FGL1 via methylating TCF12 to inhibit CD8(+) T-cell-mediated antitumor immunity in liver cancer","volume":"15","author":"Sun","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"8","key":"10.1016\/j.biopha.2025.118754_bib89","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217248","article-title":"Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERalpha(+) breast cancer","volume":"15","author":"Poulard","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.biopha.2025.118754_bib90","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.13964","article-title":"ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor","volume":"5","author":"Mounir","year":"2016","journal-title":"Elife"},{"issue":"6","key":"10.1016\/j.biopha.2025.118754_bib91","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models","volume":"11","author":"Chan-Penebre","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118754_bib92","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.bmcl.2019.03.042","article-title":"Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors","volume":"29","author":"Lin","year":"2019","journal-title":"Bioorg. Med Chem. Lett."},{"issue":"53","key":"10.1016\/j.biopha.2025.118754_bib93","doi-asserted-by":"crossref","first-page":"39653","DOI":"10.1039\/D4RA05497K","article-title":"A review of the known MTA-cooperative PRMT5 inhibitors","volume":"14","author":"Hu","year":"2024","journal-title":"RSC Adv."},{"issue":"12","key":"10.1016\/j.biopha.2025.118754_bib94","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1158\/1535-7163.MCT-21-0367","article-title":"Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity","volume":"20","author":"Brehmer","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2025.118754_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106634","article-title":"PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study","volume":"149","author":"Ferrarotto","year":"2024","journal-title":"Oral. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118754_bib96","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41375-025-02515-8","article-title":"Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies","volume":"39","author":"Bewersdorf","year":"2025","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib97","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13046-024-03270-x","article-title":"PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands","volume":"44","author":"Mishra","year":"2025","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib98","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/bloodadvances.2023010554","article-title":"Resistance to PRMT5-targeted therapy in mantle cell lymphoma","volume":"8","author":"Long","year":"2024","journal-title":"Blood Adv."},{"issue":"20","key":"10.1016\/j.biopha.2025.118754_bib99","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1182\/bloodadvances.2023009906","article-title":"PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma","volume":"7","author":"Brown-Burke","year":"2023","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41467-022-35778-1","article-title":"Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation","volume":"14","author":"Hing","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118754_bib101","article-title":"A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM), American Society","author":"Monga","year":"2023","journal-title":"Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib102","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-21-0620","article-title":"SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance","volume":"21","author":"Jensen-Pergakes","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.biopha.2025.118754_bib103","article-title":"JBI-778, a novel brain-penetrant small molecule PRMT5 inhibitor for treatment of cancer","volume":"83","author":"Sivanandhan","year":"2023","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2025.118754_bib104","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"issue":"6278","key":"10.1016\/j.biopha.2025.118754_bib105","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.biopha.2025.118754_bib106","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1021\/acs.jmedchem.4c01998","article-title":"MTA-cooperative PRMT5 inhibitors: mechanism switching through structure-based design","volume":"68","author":"Cottrell","year":"2025","journal-title":"J. Med Chem."},{"issue":"3","key":"10.1016\/j.biopha.2025.118754_bib107","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1021\/acs.jmedchem.1c01900","article-title":"Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5*MTA Complex for the Treatment of MTAP-Deleted Cancers","volume":"65","author":"Smith","year":"2022","journal-title":"J. Med Chem."},{"issue":"8","key":"10.1016\/j.biopha.2025.118754_bib108","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c00133","article-title":"Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted Cancers","volume":"67","author":"Cottrell","year":"2024","journal-title":"J. Med Chem."},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib109","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.6039","article-title":"A novel, sensitive, and fast ultra-high-performance liquid chromatography tandem mass spectrometry method for TNG908 determination in dog plasma and pharmacokinetic study","volume":"39","author":"Zhu","year":"2025","journal-title":"Biomed. Chromatogr."},{"issue":"7","key":"10.1016\/j.biopha.2025.118754_bib110","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1021\/acs.jmedchem.4c03121","article-title":"Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers","volume":"68","author":"Pettus","year":"2025","journal-title":"J. Med Chem."},{"issue":"5","key":"10.1016\/j.biopha.2025.118754_bib111","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/acs.jmedchem.4c03067","article-title":"Discovery of TNG462: a highly potent and selective MTA-cooperative PRMT5 inhibitor to target cancers with MTAP deletion","volume":"68","author":"Cottrell","year":"2025","journal-title":"J. Med Chem."},{"issue":"12","key":"10.1016\/j.biopha.2025.118754_bib112","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"17","key":"10.1016\/j.biopha.2025.118754_bib113","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1021\/acs.jmedchem.0c01111","article-title":"Discovery of first-in-class protein arginine methyltransferase 5 (PRMT5) degraders","volume":"63","author":"Shen","year":"2020","journal-title":"J. Med Chem."},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib114","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s13046-024-03237-y","article-title":"Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer","volume":"43","author":"Guo","year":"2024","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"19","key":"10.1016\/j.biopha.2025.118754_bib115","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.1074\/jbc.RA119.007640","article-title":"Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT\/beta-catenin and AKT\/GSK3beta proliferative signaling","volume":"294","author":"Chung","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib116","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nri2217","article-title":"Germinal centres: role in B-cell physiology and malignancy","volume":"8","author":"Klein","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"22","key":"10.1016\/j.biopha.2025.118754_bib117","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1182\/blood-2008-12-193037","article-title":"The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL","volume":"113","author":"Ci","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.biopha.2025.118754_bib118","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1038\/s41375-019-0489-6","article-title":"PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K\/AKT in lymphoma cells","volume":"33","author":"Zhu","year":"2019","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.biopha.2025.118754_bib119","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1038\/sj.emboj.7601794","article-title":"Low levels of miR-92b\/96 induce PRMT5 translation and H3R8\/H4R3 methylation in mantle cell lymphoma","volume":"26","author":"Pal","year":"2007","journal-title":"EMBO J."},{"issue":"10","key":"10.1016\/j.biopha.2025.118754_bib120","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.2022019419","article-title":"PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma","volume":"142","author":"Sloan","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib121","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-023-00799-6","article-title":"Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations","volume":"13","author":"Che","year":"2023","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib122","doi-asserted-by":"crossref","first-page":"9775","DOI":"10.1038\/s41598-020-66224-1","article-title":"Genomic deregulation of PRMT5 supports growth and stress tolerance in chronic lymphocytic leukemia","volume":"10","author":"Schnormeier","year":"2020","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.biopha.2025.118754_bib123","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/s41594-019-0313-z","article-title":"PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia","volume":"26","author":"Radzisheuskaya","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118754_bib124","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/onc.2017.337","article-title":"The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia","volume":"37","author":"Serio","year":"2018","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.biopha.2025.118754_bib125","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/leu.2017.206","article-title":"Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML","volume":"32","author":"Kaushik","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.biopha.2025.118754_bib126","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/leu.2017.334","article-title":"Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma","volume":"32","author":"Gulla","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2025.118754_bib127","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.879057","article-title":"Inhibition of the protein arginine methyltransferase PRMT5 in high-risk multiple myeloma as a novel treatment approach","volume":"10","author":"Vlummens","year":"2022","journal-title":"Front Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118754_bib128","article-title":"Emerging roles of protein arginine methyltransferase in multiple myeloma","volume":"33","author":"Qaddoura","year":"2025","journal-title":"Mol. Ther. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118754_bib129","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/s41419-021-04125-5","article-title":"PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma","volume":"12","author":"Xia","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2025.118754_bib130","doi-asserted-by":"crossref","DOI":"10.1177\/09636897211001772","article-title":"PRMT5 Promotes EMT Through Regulating Akt Activity in Human Lung Cancer","volume":"30","author":"Huang","year":"2021","journal-title":"Cell Transpl."},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib131","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1038\/s41467-022-31645-1","article-title":"PRMT5 activates AKT via methylation to promote tumor metastasis","volume":"13","author":"Huang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118754_bib132","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s42003-018-0275-4","article-title":"MEP50\/PRMT5-mediated methylation activates GLI1 in Hedgehog signalling through inhibition of ubiquitination by the ITCH\/NUMB complex","volume":"2","author":"Abe","year":"2019","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib133","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13046-019-1064-8","article-title":"The arginine methyltransferase PRMT5 and PRMT1 distinctly regulate the degradation of anti-apoptotic protein CFLARL in human lung cancer cells","volume":"38","author":"Li","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2025.118754_bib134","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009600","article-title":"MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors","volume":"12","author":"Chen","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118754_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118240","article-title":"Drug discovery targeting protein arginine methyltransferase 5 (PRMT5): an update","volume":"128","author":"Gu","year":"2025","journal-title":"Bioorg. Med Chem."},{"key":"10.1016\/j.biopha.2025.118754_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215594","article-title":"Arginine methyltransferase PRMT5 methylates and destabilizes Mxi1 to confer radioresistance in non-small cell lung cancer","volume":"532","author":"Yang","year":"2022","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.biopha.2025.118754_bib137","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317695917","article-title":"Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer","volume":"39","author":"Wu","year":"2017","journal-title":"Tumour Biol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118754_bib138","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10549-017-4597-6","article-title":"PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer","volume":"168","author":"Wang","year":"2018","journal-title":"Breast Cancer Res Treat."},{"issue":"18","key":"10.1016\/j.biopha.2025.118754_bib139","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1038\/onc.2010.591","article-title":"Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion","volume":"30","author":"Yu","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118754_bib140","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ebiom.2019.05.011","article-title":"A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy","volume":"44","author":"Zhou","year":"2019","journal-title":"EBioMedicine"},{"issue":"16","key":"10.1016\/j.biopha.2025.118754_bib141","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1158\/0008-5472.CAN-11-0458","article-title":"Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4","volume":"71","author":"Powers","year":"2011","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib142","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13046-022-02400-7","article-title":"The PRMT5-LSD1 axis confers Slug dual transcriptional activities and promotes breast cancer progression","volume":"41","author":"Zhang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"7","key":"10.1016\/j.biopha.2025.118754_bib143","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/j.ymthe.2022.03.003","article-title":"PRMT5 regulates RNA m6A demethylation for doxorubicin sensitivity in breast cancer","volume":"30","author":"Wu","year":"2022","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2025.118754_bib144","article-title":"PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition","volume":"4","author":"Li","year":"2023","journal-title":"Cell Rep. Med"},{"issue":"2","key":"10.1016\/j.biopha.2025.118754_bib145","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/onc.2016.199","article-title":"PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells","volume":"36","author":"Banasavadi-Siddegowda","year":"2017","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib146","article-title":"Targeting protein arginine methyltransferase 5 sensitizes glioblastoma to trametinib","volume":"4","author":"Banasavadi-Siddegowda","year":"2022","journal-title":"Neurooncol Adv."},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib147","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/s41467-021-21204-5","article-title":"PRMT5 inhibition disrupts splicing and stemness in glioblastoma","volume":"12","author":"Sachamitr","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib148","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41420-025-02323-0","article-title":"The emerging roles of aberrant alternative splicing in glioma","volume":"11","author":"Ben Mrid","year":"2025","journal-title":"Cell Death Discov."},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib149","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-019-03274-0","article-title":"The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma","volume":"145","author":"Holmes","year":"2019","journal-title":"J. Neurooncol"},{"issue":"12","key":"10.1016\/j.biopha.2025.118754_bib150","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118754_bib151","article-title":"Evaluation of the impact of homozygous MTAP truncations on the activity and selectivity of MTA-cooperative PRMT5 inhibitors","volume":"84","author":"Tonini","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118754_bib152","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1158\/2159-8290.CD-24-0887","article-title":"AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers","volume":"15","author":"Belmontes","year":"2025","journal-title":"Cancer Discov."},{"issue":"18","key":"10.1016\/j.biopha.2025.118754_bib153","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-25-1507","article-title":"Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer","volume":"85","author":"Drizyte-Miller","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.118754_bib154","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241275376","article-title":"Phase I\/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms","volume":"15","author":"Watts","year":"2024","journal-title":"Ther. Adv. Hematol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118754_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2024.07.1618","article-title":"Adjuvant Ruthenium Plaque Brachytherapy (BRT) after Partial Lamellar Vitreo-Uvectomy (PLSU) for Medium-Large Uveal Melanoma (UM)","volume":"120","author":"Boutrus","year":"2024","journal-title":"Int J. Radiat. Oncol."},{"key":"10.1016\/j.biopha.2025.118754_bib156","doi-asserted-by":"crossref","first-page":"16742","DOI":"10.1182\/blood-2024-203060","article-title":"PRIMAVERA: A Modular Phase I\/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed\/Refractory Hematologic Malignancies","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.biopha.2025.118754_bib157","article-title":"Trial in progress: A first-in-human phase 1a\/b study of BGB-58067, an MTA-cooperative PRMT5 inhibitor, in patients with advanced solid tumors and MTAP deficiency Free","volume":"85","author":"Van Tine","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118754_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.651","article-title":"First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers","volume":"31","author":"Villar","year":"2020","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.biopha.2025.118754_bib159","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1158\/1078-0432.CCR-23-0092","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in advanced solid tumors","volume":"29","author":"Vieito","year":"2023","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2025.118754_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107390","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes","volume":"134","author":"Haque","year":"2023","journal-title":"Leuk. Res"},{"key":"10.1016\/j.biopha.2025.118754_bib161","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-146987","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes","volume":"138","author":"Haque","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118754_bib162","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-205802","article-title":"Mechanistic insights and therapeutic potential of a PRMT5 inhibitor combined with venetoclax in B cell malignancies","volume":"144","author":"Zhu","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.biopha.2025.118754_bib163","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1021\/acsmedchemlett.8b00014","article-title":"LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity","volume":"9","author":"Bonday","year":"2018","journal-title":"ACS Med Chem Lett"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:47:44Z","timestamp":1777574864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225009485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":163,"alternative-id":["S0753332225009485"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118754","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting PRMT5 in cancer: Mechanistic insights and clinical progress","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118754"}}